Januvia (Sitagliptin) Flashcards
12 Questions
100 Views

Januvia (Sitagliptin) Flashcards

Created by
@AmicableNeodymium

Questions and Answers

What is the drug class of Januvia?

  • Antidiabetic
  • DPP4 inhibitor
  • Both A and B (correct)
  • None of the above
  • What is the route of administration for Januvia?

    oral

    What is the recommended dose of Januvia for Type 2 diabetes mellitus?

    100 mg orally once daily

    What are the indications for using Januvia?

    <p>Type 2 DM</p> Signup and view all the answers

    What is the dose adjustment for mild renal insufficiency (CrCl 50 mL/min or greater)?

    <p>No adjustment needed</p> Signup and view all the answers

    Can Januvia be taken with food?

    <p>Yes</p> Signup and view all the answers

    Serious hypersensitivity reactions have been reported as contraindications for Januvia.

    <p>True</p> Signup and view all the answers

    Which of the following are precautions associated with Januvia?

    <p>All of the above</p> Signup and view all the answers

    What are some common adverse effects of Januvia?

    <p>Hypoglycemia, Headache, Nasopharyngitis</p> Signup and view all the answers

    What pregnancy category is Januvia classified under?

    <p>B</p> Signup and view all the answers

    What is the bioavailability of orally administered Januvia?

    <p>87%</p> Signup and view all the answers

    What is the mechanism of action of Sitagliptin?

    <p>Dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor</p> Signup and view all the answers

    Study Notes

    Januvia (Sitagliptin) Overview

    • Belongs to antidiabetic drug class as a DPP4 inhibitor.
    • Administered via oral route.

    Dosing Information

    • Used for Type 2 diabetes only; not for Type 1 diabetes or diabetic ketoacidosis.
    • General dosing: 100 mg orally once daily with or without food.
    • Dosage may need adjustment when combined with sulfonylureas or insulin.

    Dose Adjustments

    • For renal insufficiency:
      • Mild (CrCl ≥ 50 mL/min): no adjustment necessary.
      • Moderate (CrCl 30-50 mL/min): 50 mg orally once daily.
      • Severe (CrCl < 30 mL/min): 25 mg orally once daily.
      • ESRD on dialysis: 25 mg orally once daily, regardless of dialysis timing.
    • Mild to moderate hepatic insufficiency: no adjustment needed.
    • No adjustments based solely on age for elderly patients.

    Administration Guidelines

    • Can be taken with or without food.

    Contraindications

    • Serious hypersensitivity reactions to sitagliptin, such as angioedema or anaphylaxis.

    Precautions

    • Watch for angioedema; potential for cross-sensitivity with other DPP-4 inhibitors unknown.
    • Monitor for acute pancreatitis; therapy should be discontinued if symptoms develop.
    • Serious hypersensitivity reactions, including Stevens-Johnson syndrome, can occur, especially within the first three months.
    • Reported severe joint pain may necessitate discontinuation and could recur with rechallenge.
    • Regularly monitor renal function, especially in cases of worsening renal function or ESRD.

    Adverse Effects

    • Common effects:
      • Hypoglycemia (0.6% to 12.2%)
      • Headache (1.1% to 5.9%)
      • Nasopharyngitis (5.2% to 6.3%); Upper respiratory infections (4.5% to 6.3%)
    • Serious effects:
      • Pancreatic cancer, pancreatitis, anaphylaxis, angioedema, Stevens-Johnson syndrome, and rhabdomyolysis.

    Drug Interactions

    • Interactions with somatostatin, digoxin (Lanoxicaps, Lanoxin), insulin, and several oral diabetes medications.
    • Potential interactions with fluoroquinolones.

    Pregnancy Category

    • Rated category B, indicating no known risk in human studies.

    Monitoring Requirements

    • Regular assessments of glycemic control through HbA1c:
      • Every 6 months in patients meeting goals.
      • Every 3 months if therapy changes or goals not met.
    • Self-monitoring of blood glucose as needed.
    • Periodic renal function assessments.

    Mechanism of Action (MOA)

    • Inhibits DPP-4 enzyme, preserving incretin hormones like GLP-1 and GIP that regulate glucose homeostasis post-meal.
    • Enhances insulin release and decreases glucagon levels in a glucose-dependent manner.

    Pharmacokinetics

    • Absorption: Bioavailability is 87% when taken orally.
    • Distribution: 38% protein binding, volume of distribution is approximately 198 L.
    • Metabolism: Primarily hepatic through CYP3A4 and minor contributions from CYP2C8.

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Description

    Test your knowledge on Januvia (Sitagliptin) with these flashcards. This quiz covers essential details such as drug class, administration routes, and dosing guidelines. Perfect for students and healthcare professionals alike.

    More Quizzes Like This

    Sitagliptin (Januvia) Quiz
    9 questions
    Use Quizgecko on...
    Browser
    Browser